Reversible inhibition of sperm under guidance

Last updated
Diagram showing the site of injection of the product Vasalgel, a vasectomy alternative Vasalgel diagram.svg
Diagram showing the site of injection of the product Vasalgel, a vasectomy alternative

Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive injection developed at IIT Kharagpur in India by the team of Dr. Sujoy K. Guha.[ citation needed ]

Contents

RISUG has been patented in India, China, Bangladesh, and the United States. [1] Phase III clinical trials were underway in India, and were slowed by insufficient volunteers. [1]

Beginning in 2011, a contraceptive product based on RISUG, Vasalgel, was under development in the US by the Parsemus Foundation, who were unable to bring the product to market over the next decade. [2] In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to bring the technology to market under the name Plan A for Men. [3]

Development

Sujoy K. Guha developed RISUG after years of developing other inventions. He originally wanted to create an artificial heart that could pump blood using a strong electrical pulse. Using the 13-chamber model of a cockroach heart, he designed a softer pumping mechanism that would theoretically be safe to use in humans. [4] As India's population grew throughout the 1970s, Guha modified his heart pump design to create a water pump that could work off of differences in ionic charges between salt water and fresh water in water treatment facilities. This filtration system did not require electricity and could potentially help large groups of people have access to clean water. India, however, decided that the population problem would be better served by developing more effective contraception. So Guha again modified his design to work safely inside the body, specifically inside the male genitalia. The non-toxic polymer of RISUG also uses differences in the charges of the semen to rupture the sperm as it flows through the vas deferens. [2]

Intellectual property rights to RISUG in the United States were acquired between 2010 and 2012 by the Parsemus Foundation, a not-for-profit organization, which has branded it as "Vasalgel". [5] [6] Vasalgel, which has a slightly different formulation than RISUG, underwent animal trials in the United States, but reversibility proved unsuccessful. [7]

Mechanisms

RISUG works by an injection into the vas deferens, the vessel through which the sperm moves before ejaculation. RISUG is similar to vasectomy in that a local anesthetic is administered, an incision is made in the scrotum, and the vasa deferentia are injected with a polymer gel (rather than being cut and cauterized). [8] In a matter of minutes, the injection coats the walls of the vasa with a clear gel made of 60 mg of the copolymer styrene/maleic anhydride (SMA) with 120 µl of the solvent dimethyl sulfoxide. The copolymer is made by irradiation of the two monomers with a dose of 0.2 to 0.24 megarad for every 40 g of copolymer and a dose rate of 30 to 40 rad/s. Dr Pradeep K. Jha, a senior scientist, worked on the effects of gamma dose rate and total dose interrelation on molecular designing and biological function of polymer. [9] The source of irradiation is cobalt-60 gamma radiation.[ citation needed ]

The effect the chemical has on sperm is not completely understood. Originally, researchers thought it lowered the pH of the environment enough to kill the sperm. [10]

Guha theorizes that the polymer surface has a negative and positive electric charge mosaic. Within an hour after placement the differential charge from the gel will rupture the sperm's cell membrane as it passes through the vas, deactivating it before it can exit from the body. [11]

Safety

The thoroughness of carcinogenicity and toxicity testing in clinical trials had been questioned after phase I of clinical trials on the basis of presence of styrene and maleic anhydride in the formulation. In response, Guha argued that substances can be individually toxic in nature but harmless as compounds like pure chlorine, which can melt human flesh on its own, but, when combined with sodium, it becomes sodium chloride – the basic salt that people consume in their diets. When it did not persuade ICMR and the clinical trials did not resume by 1996, he went to the Supreme court and the next round of clinical trials resumed afterwards. [12]

In October 2002, India's Ministry of Health aborted the clinical trials due to reports of albumin in urine [13] and scrotal swelling in phase III trial participants. Although the ICMR has reviewed and approved the toxicology data three times, WHO and Indian researchers say that the studies were not done according to recent international standards. Due to the lack of any evidence for adverse effects, trials were restarted in 2011. [2] Guha says concerns over the safety and efficacy of the drug have mainly come from the NIH and WHO. [12]

Availability and marketing

By November 2019, the ICMR had successfully completed clinical trials of the world's first injectable male contraceptive, which was then sent to the Drug Controller General of India (DCGI) for regulatory approval. The trials were over, including extended, phase III clinical trials, for which 303 candidates were recruited with 97.3% success rate and no reported side effects. [14]

In the developed world, the average time taken for a drug to go from concept to market is 10 to 15 years, whereas, it has been over four decades since Guha published his original paper on RISUG. [12] RISUG aims to provide males with years-long fertility control, thereby overcoming compliance problems and avoiding ongoing costs associated with condoms and the female birth control pill, which must be taken daily. [15]

Pharmaceutical companies have expressed little interest in RISUG. [16] One obstacle facing marketing of the product is that men generally perceive contraception as a woman's issue.[ citation needed ] Men may choose not to use alternative methods of contraception because there are fewer options for birth control for them than there are for women[ dubious – discuss ], or they may fear the side effects, or it may conflict with their cultural or religious beliefs. [16] However, the same study published that in the year 2000, an international survey found that 83% of men were willing to use a male contraceptive. [16] Despite this, pharmaceutical companies are reluctant to lose market share of a thriving global market for female contraceptives and condoms which bring billions of dollars of revenue each year.[ citation needed ] Initially, RISUG attracted some interest from pharmaceutical companies. However, considering that RISUG is an inexpensive, one-time procedure, manufacturers retracted.

Smart RISUG

Smart RISUG is a newer version of the male contraception that was published in 2009. The polymer adds iron oxide and copper particles to the original compound, giving it magnetic properties and the name "Smart RISUG". After injection the exact location of the polymer inside the vas deferens can be measured and visualized by X-ray and magnetic resonance imaging. The polymer location can also be externally controlled using a pulsed magnetic field. With this magnetic field, the polymer can change location inside the body to maximize sterility or can be removed to restore fertility. The polymer has magnetoelastic behavior that allows it to stretch and elongate to better line the vas deferens. The iron oxide component is necessary to prevent agglomeration.

With the presence of iron particles, the polymer has lower protein binding and therefore prevents agglomeration. The copper particles in the compound allow the polymer to conduct heat. When an external microwave applies heat to the polymer, it can liquify the polymer again to be excreted to restore fertility. Smart RISUG is therefore a better choice for men who want to use RISUG as temporary birth control, since it does not require a second surgery to restore fertility. The addition of metal ions also increases the effectiveness of the spermicide. The low frequency electromagnetic field disintegrates the sperm cell membrane in the head region. This in turn causes both acrosin and hyaluronidase enzymes to leak out of the sperm, making the sperm infertile.

The safety of Smart RISUG is uncertain and requires additional research. The spermicidal properties of the compound should not have negative effects on the lining of the vas deferens. Albino rats used to develop the new polymer did not have any adverse symptoms. [17] The original compound had been tested for over 25 years in rats. [7]

Related Research Articles

<span class="mw-page-title-main">Vasectomy</span> Surgical procedure for male sterilization

Vasectomy is an elective surgical procedure that results in male sterilization, often as a means of permanent contraception. During the procedure, the male vasa deferentia are cut and tied or sealed so as to prevent sperm from entering into the urethra and thereby prevent fertilization of a female through sexual intercourse. Vasectomies are usually performed in a physician's office, medical clinic, or, when performed on a non-human animal, in a veterinary clinic. Hospitalization is not normally required as the procedure is not complicated, the incisions are small, and the necessary equipment routine.

<span class="mw-page-title-main">Vas deferens</span> Part of the male reproductive system of many vertebrates

The vas deferens, with the more modern name ductus deferens, is part of the male reproductive system of many vertebrates. The ducts transport sperm from the epididymides to the ejaculatory ducts in anticipation of ejaculation. The vas deferens is a partially coiled tube which exits the abdominal cavity through the inguinal canal.

<span class="mw-page-title-main">Vas-occlusive contraception</span> Form of male contraception that blocks sperm transport in the vas deferens

Vas-occlusive contraception is a form of male contraception that blocks sperm transport in the vas deferens, the tubes that carry sperm from the epididymis to the ejaculatory ducts.

Male contraceptives, also known as male birth control, are methods of preventing pregnancy by interrupting the function of sperm. The main forms of male contraception available today are condoms, vasectomy, and withdrawal, which together represented 20% of global contraceptive use in 2019. New forms of male contraception are in clinical and preclinical stages of research and development, but as of 2024, none have reached regulatory approval for widespread use.

Sujoy Kumar Guha is an Indian biomedical engineer. He was born in Patna, India, 20 June 1940. He did his undergraduate degree (B.Tech.) in electrical engineering from IIT Kharagpur, followed by a master's degree in electrical engineering at IIT, and another master's degree from the University of Illinois, Urbana-Champaign. Guha later received his Ph.D. in medical physiology from St. Louis University.

<span class="mw-page-title-main">Hormonal contraception</span> Birth control methods that act on the endocrine system

Hormonal contraception refers to birth control methods that act on the endocrine system. Almost all methods are composed of steroid hormones, although in India one selective estrogen receptor modulator is marketed as a contraceptive. The original hormonal method—the combined oral contraceptive pill—was first marketed as a contraceptive in 1960. In the ensuing decades, many other delivery methods have been developed, although the oral and injectable methods are by far the most popular. Hormonal contraception is highly effective: when taken on the prescribed schedule, users of steroid hormone methods experience pregnancy rates of less than 1% per year. Perfect-use pregnancy rates for most hormonal contraceptives are usually around the 0.3% rate or less. Currently available methods can only be used by women; the development of a male hormonal contraceptive is an active research area.

<span class="mw-page-title-main">Comparison of birth control methods</span>

There are many methods of birth control that vary in requirements, side effects, and effectiveness. As the technology, education, and awareness about contraception has evolved, new contraception methods have been theorized and put in application. Although no method of birth control is ideal for every user, some methods remain more effective, affordable or intrusive than others. Outlined here are the different types of barrier methods, hormonal methods, various methods including spermicides, emergency contraceptives, and surgical methods and a comparison between them.

Immunocontraception is the use of an animal's immune system to prevent it from fertilizing offspring. Contraceptives of this type are not currently approved for human use.

<span class="mw-page-title-main">Styrene maleic anhydride</span> Chemical compound

Styrene maleic anhydride is a synthetic polymer that is built-up of styrene and maleic anhydride monomers. The monomers can be almost perfectly alternating, making it an alternating copolymer, but (random) copolymerisation with less than 50% maleic anhydride content is also possible. The polymer is formed by a radical polymerization, using an organic peroxide as the initiator. The main characteristics of SMA copolymer are its transparent appearance, high heat resistance, high dimensional stability, and the specific reactivity of the anhydride groups. The latter feature results in the solubility of SMA in alkaline (water-based) solutions and dispersion.

Combined injectable contraceptives (CICs) are a form of hormonal birth control for women. They consist of monthly injections of combined formulations containing an estrogen and a progestin to prevent pregnancy.

<span class="mw-page-title-main">Contraceptive implant</span> Implantable medical device used for birth control

A contraceptive implant is an implantable medical device used for the purpose of birth control. The implant may depend on the timed release of hormones to hinder ovulation or sperm development, the ability of copper to act as a natural spermicide within the uterus, or it may work using a non-hormonal, physical blocking mechanism. As with other contraceptives, a contraceptive implant is designed to prevent pregnancy, but it does not protect against sexually transmitted infections.

<span class="mw-page-title-main">Birth control</span> Method of preventing human pregnancy

Birth control, also known as contraception, anticonception, and fertility control, is the use of methods or devices to prevent unintended pregnancy. Birth control has been used since ancient times, but effective and safe methods of birth control only became available in the 20th century. Planning, making available, and using human birth control is called family planning. Some cultures limit or discourage access to birth control because they consider it to be morally, religiously, or politically undesirable.

Vasectomy reversal is a term used for surgical procedures that reconnect the male reproductive tract after interruption by a vasectomy. Two procedures are possible at the time of vasectomy reversal: vasovasostomy and vasoepididymostomy. Although vasectomy is considered a permanent form of contraception, advances in microsurgery have improved the success of vasectomy reversal procedures. The procedures remain technically demanding and may not restore the pre-vasectomy condition.

<span class="mw-page-title-main">Algestone acetophenide</span> Chemical compound

Algestone acetophenide, also known more commonly as dihydroxyprogesterone acetophenide (DHPA) and sold under the brand names Perlutal and Topasel among others, is a progestin medication which is used in combination with an estrogen as a form of long-lasting injectable birth control. It has also been used alone, but is no longer available as a standalone medication. DHPA is not active by mouth and is given once a month by injection into muscle.

<span class="mw-page-title-main">Medroxyprogesterone acetate</span> Injectable form of birth control

Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. It is used as a method of birth control and as a part of menopausal hormone therapy. It is also used to treat endometriosis, abnormal uterine bleeding, paraphilia, and certain types of cancer. The medication is available both alone and in combination with an estrogen. It is taken by mouth, used under the tongue, or by injection into a muscle or fat.

<span class="mw-page-title-main">Norethisterone enanthate</span> Chemical compound

Norethisterone enanthate (NETE), also known as norethindrone enanthate, is a form of hormonal birth control which is used to prevent pregnancy in women. It is used both as a form of progestogen-only injectable birth control and in combined injectable birth control formulations. It may be used following childbirth, miscarriage, or abortion. The failure rate per year in preventing pregnancy for the progestogen-only formulation is 2 per 100 women. Each dose of this form lasts two months with only up to two doses typically recommended.

<span class="mw-page-title-main">Estradiol enantate</span> Chemical compound

Estradiol enantate, also spelled estradiol enanthate and sold under the brand names Perlutal and Topasel among others, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide, a progestin, and is used specifically as a combined injectable contraceptive. Estradiol enantate is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month.

<span class="mw-page-title-main">Levonorgestrel butanoate</span> Chemical compound

Levonorgestrel butanoate (LNG-B), or levonorgestrel 17β-butanoate, is a steroidal progestin of the 19-nortestosterone group which was developed by the World Health Organization (WHO) in collaboration with the Contraceptive Development Branch (CDB) of the National Institute of Child Health and Human Development as a long-acting injectable contraceptive. It is the C17β butanoate ester of levonorgestrel, and acts as a prodrug of levonorgestrel in the body. The drug is at or beyond the phase III stage of clinical development, but has not been marketed at this time. It was first described in the literature, by the WHO, in 1983, and has been under investigation for potential clinical use since then.

<span class="mw-page-title-main">Estradiol enantate/algestone acetophenide</span> Pharmaceutical combination

Estradiol enantate/algestone acetophenide, also known as estradiol enantate/dihydroxyprogesterone acetophenide (E2-EN/DHPA) and sold under the brand names Perlutal and Topasel among others, is a form of combined injectable birth control which is used to prevent pregnancy. It contains estradiol enantate (E2-EN), an estrogen, and algestone acetophenide, a progestin. The medication is given once a month by injection into muscle.

<span class="mw-page-title-main">Estradiol valerate/megestrol acetate</span> Combination drug

Estradiol valerate/megestrol acetate (EV/MGA) is a combined injectable contraceptive which was developed in China in the 1980s but was never marketed. It is an aqueous suspension of microcapsules containing 5 mg estradiol valerate (EV) and 15 mg megestrol acetate (MGA). It was also studied at doses of EV ranging from 0.5 to 5 mg and at doses of MGA ranging from 15 to 25 mg.

References

  1. 1 2 Jyoti, Archana (2011-01-03). "Poor response from male volunteers hits RISUG clinical trial". The Pioneer . New Delhi. Archived from the original on 2011-06-12. Retrieved 2011-06-08.
  2. 1 2 3 Gifford, Bill (2011-04-26). "The Revolutionary New Birth Control Method for Men". Wired. Retrieved 2020-10-19.
  3. ↑ Hobbins, Katie (2023-08-22). "'Plan A' Offers a New Option in Male Birth Control". www.mddionline.com.
  4. ↑ "An Indian artificial heart". The Telegraph. April 14, 2008. Archived from the original on July 22, 2009.
  5. ↑ Beck, Melinda (2011-06-14). "'Honey, It's Your Turn...'". The Wall Street Journal. Retrieved 2012-10-13.
  6. ↑ "Parsemus Foundation". Parsemusfoundation.org. Archived from the original on 2012-10-14. Retrieved 2012-10-13.
  7. 1 2 Francis, Leslie (2017). The Oxford Handbook of Reproductive Ethics. Oxford University Press. p. 336. ISBN   978-0-19-998187-8.
  8. ↑ "Expanding Options for Male Contraception". Planned Parenthood Advocates of Arizona. 2011-08-08. Retrieved 2012-03-28.
  9. ↑ Jha, Pradeep K.; Jha, Rakhi; Gupta, B.L.; Guha, Sujoy K. (May 2010). "Effect of γ-dose rate and total dose interrelation on the polymeric hydrogel: A novel injectable male contraceptive". Radiation Physics and Chemistry. 79 (5): 663–671. Bibcode:2010RaPC...79..663J. doi:10.1016/j.radphyschem.2009.11.010.
  10. ↑ Archived March 17, 2005, at the Wayback Machine
  11. ↑ "RISUG". MaleContraceptives.org. 2011-07-27. Retrieved 2013-10-30.
  12. 1 2 3 "The Professor Who Had to Spend Half His Life to Make the Drug India Needs". The Wire. 2016-11-17. Retrieved 2020-10-19.
  13. ↑ Indian Ministry of Health & Family Welfare (2002-10-11). "PIB Press Releases". archive.pib.gov.in. Archived from the original on 2023-06-04. Retrieved 2023-10-31.
  14. ↑ Kaul, Rhythma (19 November 2019). "India closer to world's first male contraceptive injection". Hindustan Times .
  15. ↑ Altstedter, Ari (29 March 2017). "A New Kind of Male Birth Control Is Coming". Bloomberg.
  16. 1 2 3 Khilwani, Barkha; Badar, Ayesha; Ansari, Abdul S.; Lohiya, Nirmal K. (December 2020). "RISUG® as a male contraceptive: journey from bench to bedside". Basic and Clinical Andrology. 30 (1): 2. doi: 10.1186/s12610-020-0099-1 . PMC   7017607 . PMID   32082579.
  17. ↑ Jha, Rakhi K; Jha, Pradeep K; Guha, Sujoy K (2009). "Smart RISUG: A potential new contraceptive and its magnetic field-mediated sperm interaction". International Journal of Nanomedicine. 4: 55–64. doi: 10.2147/ijn.s4818 . ISSN   1176-9114. PMC   2720737 . PMID   19421370.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.